MARKET

TTNP

TTNP

Titan Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.930
-0.040
-2.03%
Closed 17:29 09/21 EDT
OPEN
1.960
PREV CLOSE
1.970
HIGH
1.960
LOW
1.910
VOLUME
62.68K
TURNOVER
--
52 WEEK HIGH
8.85
52 WEEK LOW
1.910
MARKET CAP
19.04M
P/E (TTM)
7.46
1D
5D
1M
3M
1Y
5Y
Titan Medical Granted U.S. Patent Titled 'Alignment difference safety in a master-slave robotic system'
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6826&f=G&l=50&d=PTXT&p=137&S1=20210831&OS=20210831&RS=20210831
Benzinga · 08/31 13:53
Here's Why Titan Pharmaceuticals (NASDAQ:TTNP) Must Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Simply Wall St. · 08/20 18:52
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
10 Pharma Companies Making Treatment for Opioid Overdose
In this article, we discuss the 10 pharma companies making treatment for opioid overdose. If you want to skip our detailed analysis of these stocks, go directly to the 5 Pharma Companies Making Treatment for Opioid Overdose. On July 21, a group of four sta...
Insider Monkey · 08/04 13:34
BRIEF-Titan Announces Positive Results From The First Studies Of TP-2021 Implant
reuters.com · 06/23 12:34
Titan Pharma reports positive TP-2021 implant results in animal model of chronic pruritus
Titan Pharmaceuticals (TTNP) announces that the in vivo study, ProNeura-based implant TP-2021 in an itch-induced mouse model, has demonstrated the potential to provide extended efficacy and durability in the treatment
Seekingalpha · 06/23 12:32
Healthcare names dominate premarket gainers
SeaChange International (SEAC) +26% on insider buying.ReTo Eco-Solutions (RETO) +21% after announcing new iron tailings project.Achieve Life Sciences (ACHV) +17%.Jiuzi Holdings, Inc. (JZXN) +15%.Tiziana Life Sciences PLC (TLSA) +11% on agreement with FHI
Seekingalpha · 06/23 12:23
Titan Announces Results From First Studies Of TP-2021 Implant In Established Animal Model Of Chronic Pruritus
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced that the in vivo study of its human kappa-opioid receptor agonist ("TP-2021," formerly JT-09) ProNeura®-based implant in an established
Benzinga · 06/23 12:08
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TTNP. Analyze the recent business situations of Titan Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TTNP stock price target is 7.00 with a high estimate of 7.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 41
Institutional Holdings: 658.93K
% Owned: 6.68%
Shares Outstanding: 9.86M
TypeInstitutionsShares
Increased
4
357.52K
New
6
42.46K
Decreased
6
68.31K
Sold Out
6
82.98K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.40%
Pharmaceuticals & Medical Research
+0.74%
Key Executives
Chairman/Chief Executive Officer/Executive Director
Marc Rubin
President/Chief Operating Officer/Chief Scientific Officer/Director
Katherine DeVarney
Independent Director
Joseph Akers
Independent Director
M. David MacFarlane
Independent Director
James McNab
Independent Director
Scott Smith
No Data
About TTNP
Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company's segment is engaged in the development of pharmaceutical products. The Company's product development programs utilize its long-term drug delivery platform, ProNeura. The Company's drug candidate, Probuphine, is being developed for the long-term maintenance treatment of opioid dependence. Titan's ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs, the first one with a ropinirole implant for the treatment of Parkinson's disease (PD) and the second one with a Triiodothyronine (T3) implant for the treatment of hypothyroidism.

Webull offers kinds of Titan Pharmaceuticals, Inc. stock information, including NASDAQ:TTNP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TTNP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TTNP stock methods without spending real money on the virtual paper trading platform.